Allergan (NYSE: AGN) has said it sees second-half revenues of over $8 billion following the sale of its generics business to Israel-based Teva Pharmaceutical Industries (NYSE: TEVA), ahead of analyst estimates.
The company said it plans to report its generics business as discontinued operations in the third quarter. The sale is expected to close in the first quarter of 2016.
Allergan said it expects adjusted earnings of $6.25 to $6.65 per share for the second half.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze